"Semaglutide is the first of many licensed agents to be tested using the InsuJet™ device. Laboratory results received on October 5th, 2023, from Basic Pharma showed no differences were detected between the use of the Ozempic® pen and the InsuJet™ needle free device. No degradants were detected from the use of the InsuJet™ device via HPLC (High-Performance Liquid Chromatography) analysis of the liquid. This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.
